1850

At 18 Borgo SS Apostoli in Florence, Pietro Malesci founded a "Drugstore and Pharmacy “ in 1850. Dr. Pietro was a chemist-pharmacist with remarkable entrepreneurial skills and great foresight.
From that shop, in fact, a business began that led to the Malesci Pharmacobiological Institute becoming one of first fully Italian-capital companies in Italy.

1946

The first registration in Italy of a xanthine-based preparation dates back to 1946. This was destined to remain, with all its derivatives, a fundamental drug for the treatment of asthma attacks and bronchoconstriction.
In November 1966, the flood in Florence did not spare the Malesci research facilities and laboratories, which for some years had been relocated near the Santa Maria Novella station, not far from the banks of the River Arno. Thanks to the efforts of the entire workforce, including managers, researchers, office workers and unskilled workers, the Company was quickly able to resume business.
During those years, in addition to consolidating its role as a leading company in sectors such as cardiology and pneumology, Malesci promotes a series of scientific and editorial initiatives such as the magazine Cardiologia Practica [Practical Cardiology] and Le Giornate Scientifiche Malesci [Malesci Science Days]. It patented and registered some molecules such as antiarhythmic and new theophyllines.

1990

From the 1990s to today, Malesci has enriched its list of high-profile molecules, belonging of the most used pharmacological classes, among which are proton pump inhibitors for the treatment of acid-related pathologies.
These drugs, which act in the final process of gastric secretion, have become the benchmark for the medical treatment of these diseases, gradually replacing more obsolete drugs.

2005

In 2005, another milestone in the history of the company was the marketing of a drug, the molecule belonging to the class of Angiotensin II antagonist or sartans, effective in the treatment of arterial hypertension.
Malesci is constantly committed to providing the medical profession with scientific information and training by organising ECM conferences and courses relevant to the company's therapeutic areas.

2019

In 2019, Malesci ehnances its image in cardiology with the launch of a third generation beta blocker, a Menarini research molecule, indicated for arterial hypertension and heart failure.

1896

Peter's son, Carlo, following in his father’s footsteps, founded a Pharmaceutical Laboratory next to the old shop in 1896. This laboratory developed and expanded on the production techniques for galenic preparations and medicinal specialties, such as Iperbiotine Malesci, a restorative tonic that was widely distributed in Italy And Latin America.
The successes achieved and the forward-thinking choice to concentrate on the production of drugs for the treatment of cardiovascular disease, led to the construction of a new headquarters in the Florentine neighbourhood of Campo di Marte.
Unfortunately, almost as soon as it was completed, in September 1943, it was destroyed in a bombing during World War II; so production continued at the shops in Borgo SS Apostoli.
During this period, Malesci laid the foundations for achieving market leadership in the field of pneumology, which it still holds to this day in Italy.

1978

In 1978, Malesci joined the Menarini Group, the leading pharmaceutical organisation in Italy and one of the most important internationally.

2002

In 2002, Malesci reached another important milestone in gastroenterology, presenting the first second-generation acid pump inhibitor to the medical profession.
Consistent with its cardiological tradition, Malesci counts among its products antihypertensive drugs for the prevention and treatment of the most widespread cardiovascular pathologies, with drugs that have remarkable therapeutic potential.
Included in therapeutic areas in which Malesci operates is antibiotic therapy, which is of considerable importance for the treatment of the most common infectious diseases.

2012

In 2012, Malesci renewed its commitment in the respiratory field with a latest-generation, non-sedative antihistamine for the treatment of allergic rhinitis (and urticaria).